

Index

- A**
- ABT-199/Venetoclax, 471, 473
 - Action potential (AP), 407
 - Activin-A, 389
 - AD. See Alzheimer's disease
 - ADAM10, 551
 - Addiction. See Drug addiction
 - Adenylyl cyclase, CRAC channel calcium modulation, 72–73
 - Aging
 - brain
 - Alzheimer's disease
 - amyloid- β effects on calcium dynamics, 549–550
 - astrogliopathy, 548–549
 - calcium signaling in astrocytes, 549–552
 - endoplasmic reticulum calcium release and astroglial response, 552
 - astrocyte
 - astroglia support over life, 546–547
 - ionic signaling and excitability, 547
 - physiology in aging, 547–548
 - overview, 545–546
 - tissue calcification, 534–535
 - AKAP9, 470
 - AKAP79, 75
 - ALN, 163
 - Alzheimer's disease (AD)
 - astrocyte aging
 - amyloid- β effects on calcium dynamics, 549–550
 - astrogliopathy, 548–549
 - calcium signaling in astrocytes, 549–552
 - endoplasmic reticulum calcium release and astroglial response, 552
 - calcium dysregulation, 501–502
 - calcium homeostasis
 - IP₃ receptor, 510–511
 - mitochondrial calcium handling, 512–513
 - ryanodine receptor, 511–512
 - store-operated calcium entry, 512
 - CALHM1 receptor, 510
 - epidemiology, 500
 - histopathology, 500
 - nicotinic acetylcholine receptors, 507–509
 - NMDA receptors, 503, 506–507
 - purinergic receptors, 509–510
 - AMPA receptor, 383, 506
 - AmpII, 413
 - Amyloid- β . See Alzheimer's disease
 - ANO1, 441
 - AP. See Action potential
 - Aquaporin, 441
 - ARF1, 291
 - Arteriosclerosis. See Calcification
 - ASD. See Autism spectrum disorder
 - Astrocyte
 - brain aging
 - Alzheimer's disease
 - amyloid- β effects on calcium dynamics, 549–550
 - astrogliopathy, 548–549
 - calcium signaling in astrocytes, 549–552
 - endoplasmic reticulum calcium release and astroglial response, 552
 - astroglia support over life, 546–547
 - ionic signaling and excitability, 547
 - physiology in aging, 547–548
 - transcription-dependent metabolic plasticity, 391–393
 - ATF3, 389
 - Atherosclerosis. See Calcification
 - Atrap, 164
 - Autism spectrum disorder (ASD)
 - IL1RAPL1 mutations, 296
 - parvalbumin neurons, 228–229
- B**
- BAP1, 482
 - Bcl-2
 - endoplasmic reticulum function, 465–466
 - immunity role, 465
 - IP₃ receptor interactions
 - modulators
 - Bcl-2, 134–138
 - Bcl-2L10, 140–141
 - Bcl-XL, 138–140
 - Bok stabilization, 132, 134
 - Mcl-1, 140
 - overview, 133
 - overview, 464, 466–467
 - therapeutic targeting in cancer
 - Bcl-2 and cell death signaling, 469–470
 - BIRD-2, 468–469, 490
 - prospects, 473–474
 - small molecule mimics of BIRD-2, 470–473
 - TAT-Pep2, 467–469
 - protein types and functions, 127–129, 465
 - ryanodine receptor modulation
 - Bcl-2, 141–142

Index

- Bcl-2 (*Continued*)
 Bcl-XL, 142
 overview, 141
 VDAC modulation, 142–145
BIN-1, 413
BiP/GRP78, endoplasmic reticulum function, 248–249
BIRD-2, 136, 468–469, 490
Bok, IP₃ receptor stabilization, 132, 134
Bone. See Calcification
BRAF, 485–486
Brain aging. See Aging
BTG2, 389
Buffer proteins. See Cytosolic calcium buffers
- C**
- Cab45, 253
CaBPs. See Calcium-binding proteins
CAC-NA2D2, 484
CAC-NA2D3, 485
CAD/SOAR, 39–40, 44–46, 49, 56
cADPR. See Cyclic ADP-ribose
Caenorhabditis. See Planarian flatworm
Calbindin-D9k
 functions, 232
 regulation, 232
 structure, 230–232
Calbindin-D28k
 function, 233
 regulation, 233–234
 structure, 232–233
Calcification
 calcium salt types and distribution, 528
 mineral homeostasis, 525–526
 pathological calcification
 blood vessels
 aging and senescence, 534–535
 apoptosis and necrosis, 531–532
 calcification inhibitors and triggers, 529–530
 calcium-sensing receptor, 530–531
 endoplasmic reticulum stress, 532–533
 matrix vesicle/exosome calcium release, 534
 mitochondrial calcium and mitophagy,
 533–534
 vascular smooth muscle cell calcium flux, 529
 fibrodysplasia ossificans progressiva, 536
 heart valve, 535–536
 kidney stone, 536
 osteoarthritis, 536
 overview, 527–528
 prospects for study, 536–537
 physiological calcification and calcium signaling,
 526–527
Calcineurin
 activation, 321–322
 Alzheimer's disease, 551
 calcineurin- β 1, 322
 inhibitor therapy adverse effects with cyclosporin
 A and tacrolimus
 diabetes, 329
 kidney dysfunction and hypertension, 328–329
 neurotoxicity, 329–330
 isozymes, 319–321
 short linear motif mediation of substrate recognition
 coordination of motifs during substrate
 dephosphorylation, 324–325
 LxVP motif, 323–324
 overview, 322–323
 PxlIT motif, 323
 signaling network evolution, 325–326
 substrate identification
 affinity purification–mass spectrometry, 326–327
 in silico strategies, 327–328
 overview, 326
 phosphoproteomics, 326
- Calcium
 amplitude and frequency modulation of signal, 69–70
 homeostasis overview, 202
 intracellular levels and signaling overview, 1–5
 local signals and discrete communication, 9–12
 oscillations
 high-fidelity signaling, 7–9
 spatial profile, 70–72
Calcium-binding proteins (CaBPs)
 CaBP1, 299–302
 CaBP2, 299, 301–303
 CaBP3, 298
 CaBP4, 300–304
 CaBP5, 302
 CaBP7, 298
 CaBP8, 298
 diseases, 303–304
 overview, 297–303
Calcium/calmodulin-dependent protein
 kinase II (CaMKII)
 Alzheimer's disease, 551
 autoinhibition, 267–268, 270
 calcium pulse frequency sensitivity, 273
 calmodulin trapping, 272
 glycosylation, 273–274
 hub domain stoichiometry and geometry, 274–275
 kinase domain tethering to central hub
 assembly, 270–272
 methionine oxidation, 273–274
 oocyte/egg calcium signaling, 342
 overview, 265–267
 phosphorylation, 269–270
 prospects for study, 278
 substrate capture for phosphorylation, 272–273
 subunit exchange triggered by activation, 276–278
 synapse-to-nucleus calcium-dependent
 communication, 383–384
Calcium/calmodulin-dependent protein kinase IV
 (CaMKIV), synapse-to-nucleus
 calcium-dependent communication,
 383–384
Calcium-induced calcium release (CICR), 111, 116,
202, 412–413

- Calcium-sensing receptor (CaSR), blood vessel calcification, 530–531
- Caldendrin, 301
- CALHM1 receptor, neurodegenerative disease, 510
- Calmodulin. *See also* Calcium/calmodulin-dependent protein kinase II; Calcium/calmodulin-dependent protein kinase IV
 - CRAC channel–PMCA pump signal linking, 76–77
 - diseases, 288–289
 - functional overview, 286–288
 - TRP channel interactions, 31
- Calneuron 1, 299, 302–303
- Calneuron 2, 299, 302–303
- CALNUC, Golgi function, 253
- Calreticulin
 - endoplasmic reticulum function, 247–248
 - function, 235–236
 - regulation, 236–237
 - structure, 234–235
- Calsequestrin, sarcoplasmic reticulum function, 250–251
- Calumenin, Golgi function, 253
- CaMKII. *See* Calcium/calmodulin-dependent protein kinase II
- CaMKIV. *See* Calcium/calmodulin-dependent protein kinase IV
- CAMTA1, 382, 386
- Cancer
 - calcium signaling remodeling
 - cell death, 486–487
 - metastasis, 485–486
 - ORAI1, 483, 485, 488
 - ORAI3, 481–482
 - proliferation, 483–485
 - prospects for study, 490–491
 - PTEN, 482
 - STIM, 482–483, 485, 487
 - therapeutic targeting, 488–490
 - TRPM8, 481
 - TRPV4, 481, 486–489
 - TRPV6, 481
 - tumor microenvironment, 487–488
 - IP₃ receptor–Bcl-2 interactions
 - overview, 464, 466–467
 - therapeutic targeting
 - Bcl-2 and cell death signaling, 469–470
 - BIRD-2, 468–469, 490
 - prospects, 473–474
 - small molecule mimics of BIRD-2, 470–473
 - TAT-Pep2, 467–469
 - SERCA, 480, 490
 - store-operated calcium entry, 479, 482, 485, 487
- Cardiac hypertrophy, calcium in remodeling, 420–422
- Cardiomyocyte
 - excitation–contraction coupling
 - calcium transient generation and contraction induction, 408–410
 - remodeling in disease, 417–422
 - tuning, 411–412
 - non-canonical calcium signal generation
 - IP₃ receptors, 413–415
 - mitochondrial calcium, 416–417
 - ryanodine receptor, 415–416
 - STIM/Orai, 416
 - two-pore channels, 415
 - prospects for calcium studies, 422–423
 - relaxation and calcium clearance, 410–411
 - transverse and axial tubule system and microdomain signaling, 410, 412–413
- CaSR. *See* Calcium-sensing receptor
- Catecholaminergic polymorphic ventricular tachycardia (CPVT), 418–420
- CAX, 438
- CBP, 384–386, 390
- CCK. *See* Cholecystokinin
- CD47, 531
- Cellular reticular network (CRN)
 - calcium dynamics, 245–246
 - endoplasmic reticulum
 - BiP/GRP78, 248–249
 - calreticulin, 247–248
 - GRP94, 249
 - overview, 246–247
 - protein disulfide isomerase, 249–250
 - endosome, 254
 - Golgi
 - CALNUC, 253
 - calumenin, 253
 - overview, 252–253
 - p54/NEFA, 253–254
 - mitochondria, 252
 - peroxisome, 254
 - prospects for study, 254–255
 - sarcoplasmic reticulum
 - calsequestrin, 250–251
 - HRC, 251
 - junction, 251–252
 - overview, 250
 - sarcalumenin, 252
- Cholecystokinin (CCK), 108, 439–440
- Chronic pain, synapse-to-nucleus calcium-dependent communication, 389–390
- CICR. *See* Calcium-induced calcium release
- CLN3 disease, 210–211
- CPVT. *See* Catecholaminergic polymorphic ventricular tachycardia
- CRAC channel
 - calcium tunneling through endoplasmic reticulum near Orai1 channels, 80–81
 - clustering and signal strength, 75–76
 - functional overview, 38, 43, 71
 - PMCA pump cross talk, 76–80
 - structure, 43–44
 - targets for local calcium entry
 - adenylyl cyclase, 72–73
 - NFAT, 74–75
 - phospholipase A₂, 73–74
 - PIP₅ kinase, 74
- CREB, 301, 382, 384–386, 390, 392–393

Index

- CREST, 384
CRN. See Cellular reticular network
Cyclic ADP-ribose (cADPR), cardiomyocyte signaling, 415–416
Cyclosporin A. See Calcineurin
Cytosolic calcium buffers
 binding capacity, 225
 calbindin-D9k
 functions, 232
 regulation, 232
 structure, 230–232
 calbindin-D28k
 function, 233
 regulation, 233–234
 structure, 232–233
 calcium-binding loop, 223
 calretinin
 function, 235–236
 regulation, 236–237
 structure, 234–235
 definition, 221–222, 224
 parvalbumin and oncomodulin
 functions, 226–227
 mitochondrial function, 227–228
 neurons and diseases, 228–230
 regulation, 226–227
 structure, 224
- D**
- DAG, 55, 412
DARPP-32, 469–470
DNMT3A2, 387, 390
DREAM, 3, 295, 297, 382, 384–385, 390
Drug addiction, synapse-to-nucleus calcium-dependent communication, 390
DWORF, 163–165, 411
Dystonia, 297
DYT2, 297
- E**
- ECC. See Excitation–contraction coupling
Egg. See Oocyte/egg
EMT. See Epithelial–mesenchymal transition
Endoplasmic reticulum (ER)
 calcium dynamics
 BiP/GRP78, 248–249
 calreticulin, 247–248
 GRP94, 249
 protein disulfide isomerase, 249–250
 calcium release and astroglial response
 in Alzheimer’s disease, 552
 oocyte/egg calcium concentration, 343–344
 overview, 246–247
Endoplasmic reticulum membrane–plasma membrane junction
 accessory proteins, 63–64
 agonist-dependent generation of calcium signals
 signaling complexes and membrane junctions, 57–59
 stimulus intensities and activation of SOCE, 59–60
Bcl-2 function, 465–466
CRAC channel clustering, 75–76
endoplasmic reticulum calcium store release
 IP₃ receptors, 61–62
 ryanodine receptors and T-cell receptor, 62–63
exocrine cell membrane contact sites
 overview, 437–438
 pathology, 444–445
 tethering, 442–444
Orai–STIM interactions, 42
prospects for study, 64
stress and blood vessel calcification, 532–533
TRPC channel regulation at membrane junctions, 60–61
- Endoregulin, 163
Endosome, calcium dynamics, 254
Endothelial cell, two-pore channels in differentiation, 372
Epithelial cell, two-pore channels in differentiation, 372–373
Epithelial–mesenchymal transition (EMT), cancer, 483, 486
ER. See Endoplasmic reticulum
ERK, 74, 329, 458
Excitation–contraction coupling (ECC)
 calcium transient generation and contraction induction, 408–410
 remodeling in disease, 417–422
 tuning, 411–412
Exocrine cell, calcium signaling
 apical pole membrane contact sites, 440–442
 cross talk and synergism, 442
 membrane contact sites
 overview, 437–438
 pathology, 444–445
 tethering, 442–444
 overview, 437–440
- F**
- FATE1, 193
Fetuin-A, 532
Fibrodysplasia ossificans progressiva (FOP), 536
FK506. See Calcineurin
Flatworm. See Planarian flatworm
FOP. See Fibrodysplasia ossificans progressiva
- G**
- GADD45α, 389
GADD45β, 389
GBA1, 211
GCAPs. See Guanylyl cyclase-activating proteins
GFAP, 548, 552
Glycogen phosphorylase, 391–392
Glycogen synthase, 391
Golgi
 calcium dynamics

- CALNUC, 253
 - calumenin, 253
 - p54/NEFA, 253–254
 - overview, 252–253
 - GRAMD2A, 42
 - GRK1, 292–293
 - GRP94, endoplasmic reticulum function, 249
 - Guanylyl cyclase-activating proteins (GCAPs), 290, 294, 297
 - GUCY2D, 297
- H**
- HAX-1, 164
 - HD. See Huntington's disease
 - HDAC4, 387
 - HDAC5, 387
 - Heart valve, calcification, 535–536
 - HIF. See Hypoxia-inducible factor
 - Hippocalcin, 293
 - HOMER, 57
 - HRC, sarcoplasmic reticulum function, 251
 - Huntington's disease (HD)
 - calcium dysregulation, 501, 503–504
 - calcium homeostasis
 - IP₃ receptor, 510–511
 - mitochondrial calcium handling, 512–513
 - ryanodine receptor, 511–512
 - store-operated calcium entry, 512
 - CALHM1 receptor, 510
 - epidemiology, 501
 - genetics, 501
 - nicotinic acetylcholine receptors, 507–509
 - NMDA receptors, 503, 506–507
 - purinergic receptors, 509–510
 - Hypoxia-inducible factor (HIF), 393
- I**
- IL1RAPL1, 296
 - InsP₃, 74
 - IP₃ receptor
 - accessory proteins, 6, 92–93
 - activation, 88–91
 - Bcl-2 interactions
 - overview, 464, 466–467
 - therapeutic targeting in cancer
 - Bcl-2 and cell death signaling, 469–470
 - BIRD-2, 468–469, 490
 - prospects, 473–474
 - small molecule mimics of BIRD-2, 470–473
 - TAT-Pep2, 467–469
 - CaBP1 binding, 300
 - cardiomyocyte, 413–415
 - endoplasmic reticulum calcium store release, 61–62
 - exocrine cell, 439
 - functional overview, 85–87
 - isoforms, 129
 - licensing for response, 94–96
 - mobility in membrane, 94–95
 - neurodegenerative disease, 510–511
 - prospects for study, 96
 - regulation
 - Bcl-2 proteins
 - Bcl-2, 134–138
 - Bcl-2L10, 140–141
 - Bcl-XL, 138–140
 - Bok stabilization, 132, 134
 - Mcl-1, 140
 - overview, 133
 - calcium, 87–88
 - IP₃, 87–88
 - signaling hub, 5–7, 91–94
 - structure, 6, 88–91, 129–132
 - IRBIT, 442
 - IRE1, 247
- J**
- Junctate, sarcoplasmic reticulum function, 251–252
- K**
- KchIPs. See Potassium channel-interacting proteins
 - Kidney stone, 536
 - Klotho, 535
- L**
- LETM1, 187
 - LNMA, 534
 - Long-term potentiation (LTP), 385–387, 389
 - LRRK2, 211
 - LTC₄, 73–74, 81
 - LTCC. See L-type calcium channel
 - LTP. See Long-term potentiation
 - L-type calcium channel (LTCC), 408, 410–411
 - LxVP motif. See Calcineurin
 - Lysosome
 - calcium
 - channels, 205
 - global requirement for signaling, 205
 - homeostasis, 202–203
 - local requirement for signaling, 204–205
 - measurement, 211–213
 - store filling, 203–204
 - diseases
 - aging-associated diseases, 211
 - CLN3 disease, 210–211
 - Niemann–Pick disease type C, 209–210
 - storage diseases, 209
 - NAADP receptor
 - endolysosomal physiology, 117
 - patch-clamping studies, 113–114
 - TRPML1
 - functions, 208–209
 - ion selectivity, 206–207
 - overview, 205–206
 - regulation, 207–208

Index

M

Manganism, 168
Matrix Gla protein (MGP), 530
Mcl-1
 IP₃ receptor modulation, 140
 VDAC modulation, 143–144
MCU, 186–188, 193, 227, 389, 417, 438, 485
MDR1, 490
mGluR5, 551
MGP. See Matrix Gla protein
MICU1, 417, 438
MICU2, 417, 438
Mitochondrial calcium flux
 blood vessel calcification and mitophagy, 533–534
 cardiomyocytes, 416–417
 cellular reticular network, 252
 metabolism, 192–193
 neurodegenerative disease and calcium handling, 512–513
 oocyte/egg calcium uptake, 344–345
 overview, 183–184
 permeability transition pore, 188–192
 prospects for study, 194–195
 spatial aspects, 193–194
 transporters, 185–188
MLCK, 267
MLSA1, 207
mTOR, 208
Myogenesis, two-pore channels, 362–368
Myoregulin, 163

N

NAADP receptor. *See also* Two-pore channels
 cardiomyocyte, 415
 desensitization of NAADP-evoked calcium release, 106–108
 exocrine cell, 438, 440
 functional overview, 103–104
 history of study, 104
 lysosome
 endolysosomal physiology, 117
 patch-clamping studies, 113–114
NAADP
 calcium-mobilizing activity, 104–105
 lysosomal–endoplasmic reticulum interactions, 115–116
 plasma membrane excitability modulation, 116–117
 targeted calcium stores, 105–106
 pharmacological properties, 108–109
 prospects for study, 117–118
 two-pore channels
 endolysosomal channels, 109–110
 human channel properties, 112
 overview, 109
 sea urchin egg channel properties, 111
NCLX, 186–187, 194
NCS proteins. *See* Neural calcium sensor proteins

NCX, cardiomyocyte, 410–411
Neural calcium sensor (NCS) proteins.
 See also specific proteins
 diseases, 295–297
 NCS-I, 289–292, 295–296
 overview, 289–295
Neurocalcin δ , 296–297
NFAT, 69, 74–75, 81, 329, 422, 551
NF- κ B. *See* Nuclear factor- κ B
Nicotinic acetylcholine receptors, neurodegenerative disease, 507–509
Niemann–Pick disease type C, 209–210, 212
Nir2, 63–64
NKCC1, 441
NKCC2, 328
NMDA receptor, 301, 329, 384–385, 389, 503, 506–507
NOTCH1, 488
NPAS4, 388–389
NPC1, 204, 209–210
NPPA, 420
NPPB, 420
NR4A1, 389
Nuclear factor- κ B (NF- κ B), 69, 551

O

Oncomodulin. *See* Parvalbumin
Oocyte/egg
 calcium signaling components, 338–341
 endoplasmic reticulum calcium concentration regulation, 343–344
 IP₃ receptor-mediated calcium release, 341–343
 maturation of oocytes and calcium homeostasis, 348–349
 mitochondrial calcium uptake, 344–345
 phospholipase C ζ
 domains, 350
 fertility studies, 350–352
 postfertilization calcium oscillation role, 349–350
 plasma membrane calcium channels, 345–348
Orai
 bone calcification role, 526
 cancer role
 ORAI1, 483, 485, 488
 ORAI3, 481–482
 cardiomyocyte, 416
 CRAC channels and calcium tunneling through endoplasmic reticulum near Orai1 channels, 80–81
 exocrine cell, 440, 443–444
 intracellular channels, 80
 oocyte/egg calcium signaling, 347
 SPCA regulation, 167
 STIM interactions
 cytoskeletal protein roles, 42–43
 endoplasmic reticulum membrane–plasma membrane junction, 42
 functional effects
 calcium-dependent inactivation, 48–49

- Orai channel gate activation, 46–48
 - overview, 41–42
 - structural studies, 44–46, 48
 - store-operated calcium entry, 10–11, 38–39, 56–57
- ORP5, 443
- ORP8, 443
- Osteoarthritis, 536
- Osteoblast, calcification, 526
- Osteoclastogenesis, TPC2 signaling, 370, 372
- Osteopontin, 536

- P**
- p53, 487
- p54/NEFA, Golgi function, 253–254
- Pancreatitis, 444–445
- Parkinson's disease (PD)
 - calcium dysregulation, 503, 505
 - calcium homeostasis
 - IP₃ receptor, 510–511
 - mitochondrial calcium handling, 512–513
 - ryanodine receptor, 511–512
 - store-operated calcium entry, 512
 - CALHM1 receptor, 510
 - epidemiology, 503
 - genetics, 503
 - nicotinic acetylcholine receptors, 507–509
 - NMDA receptors, 503, 506–507
 - purinergic receptors, 509–510
- Parvalbumin
 - functions, 226–227
 - mitochondrial function, 227–228
 - neurons and diseases, 228–230
 - regulation, 226–227
 - structure, 224
- PD. See Parkinson's disease
- PDH. See Pyruvate dehydrogenase
- PDI. See Protein disulfide isomerase
- PDK1, 397
- PDK3, 395
- Pentose phosphate pathway (PPP), 393
- PERK, 193–194
- Permeability transition pore, mitochondria, 188–192
- Peroxisome, calcium dynamics, 254
- Phospholamban (PLB), SERCA regulation, 162–163
- Phospholipase A₂ (PLA₂), CRAC channel calcium modulation, 73–74
- Phospholipase C (PLC)
 - functional overview, 5–6
 - PLC ζ
 - domains, 350
 - fertility studies, 350–352
 - postfertilization calcium oscillation role, 349–350
 - TRP channels and activation, 21
- Phosphorylase kinase, 391–392
- PIEZO channels, 480
- PIP₂, TRP channel interactions, 32
- PIP₅ kinase, CRAC channel calcium modulation, 74
- PKA. See Protein kinase A
- PKC. See Protein kinase C
- PLA₂. See Phospholipase A₂
- Planarian flatworm
 - experimental toolbox, 455–467
 - morphology and classification, 452–453
 - nervous system, 453–454
 - position-control genes, 455, 458
 - regeneration and calcium signaling, 457–458
 - stem cells, 454–455
- PLB. See Phospholamban
- PLC. See Phospholipase C
- PMCA
 - blood vessel calculation role, 529
 - calcium modulation, 77–78
 - cancer, 485–486
 - CRAC channel cross talk, 76–80
 - diseases, 170–171
 - exocrine cell, 438, 440–441
 - functional overview, 70–73
 - isoforms, 169
 - oocyte/egg calcium signaling, 344
 - overview, 168–169
 - regulation, 169–170
 - SERCA homology, 166
 - STIM suppression, 78–80
- Potassium channel-interacting proteins (KChIPs), 290, 292, 294–295, 297
- PPP. See Pentose phosphate pathway
- Praziquantel (PZQ), 457–458
- Protein disulfide isomerase (PDI), endoplasmic reticulum function, 249–250
- Protein kinase A (PKA)
 - excitation–contraction coupling, 411
 - exocrine cell, 442
 - oocyte/egg calcium signaling, 342–343
- Protein kinase C (PKC), oocyte/egg calcium signaling, 342–343
- Proton/calcium exchanger, mitochondria, 186–187, 194
- PSEN1, 211
- PTEN, 482
- Purinergic receptor, 70, 117, 205, 509–510, 550
- PxlIT motif. See Calcineurin
- Pyruvate dehydrogenase (PDH), 395, 397
- PZQ. See Praziquantel

- R**
- RACK1, 57
- RASSF4, 63
- Recoverin, 293–294
- Regeneration. See Planarian flatworm
- Ryanodine receptor (RyR)
 - Bcl-2 protein modulation
 - Bcl-2, 141–142
 - Bcl-XL, 142
 - overview, 141
 - cardiomyocyte, 410, 415–416, 418, 420

Index

- Ryanodine receptor (RyR) (*Continued*)
 endoplasmic reticulum calcium store
 release, 62–63
 neurodegenerative disease, 511–512
 overview, 11
 structure, 88
RyR. See Ryanodine receptor
- S**
- S100. See Calbindin-D9k
SAP97, 551
Sarcalumenin, sarcoplasmic reticulum function, 252
Sarcolipin (SLN), SERCA regulation, 163
Sarcoplasmic reticulum (SR)
 calcium dynamics
 calsequestrin, 250–251
 HRC, 251
 junctate, 251–252
 sarcalumenin, 252
 overview, 250
Schizophrenia, parvalbumin neurons, 229–230
SERCA
 cancer, 480, 490
 cardiomyocyte, 410–411, 418, 422
 conservation and modulation, 159
 diseases, 164–165
 exocrine cell, 440
 functional overview, 159–160
 isoforms, 160, 162
 oocyte/egg calcium signaling, 343–344
 overview, 56, 81
 PMCA homology, 156
 regulation, 162–164
 SERCA1a, 157–159
SerpinB2, 389
Serum response factor (SRF), 385
SIK2, 488
SLC12A3, 328
SLN. See Sarcolipin
SNAP-25, 285
SNAREs, 285
SNCA, 503
SOCE. See Store-operated calcium entry
SPAK, 442
SPCA
 diseases, 167–168
 exocrine cell, 440
 isoforms, 166–167
 overview, 155, 165–166
 regulation, 167
 structure, 165–166
SPO11, 382
SR. See Sarcoplasmic reticulum
SRF. See Serum response factor
Stat5, 75
STIM
 activation by store depletion, 39–41
 adenyllyl cyclase interactions, 73
 cancer, 482–483, 485, 487
 cardiomyocyte, 416, 420
 exocrine cell, 438, 440, 442–445
 functional overview, 10–11, 38–39, 56, 59–60, 85
 intracellular Orai1 channel regulation, 80
 oocyte/egg calcium signaling, 347
 Orai interactions
 cytoskeletal protein roles, 42–43
 endoplasmic reticulum membrane–plasma
 membrane junction, 42
 functional effects
 calcium-dependent inactivation, 48–49
 Orai channel gate activation, 46–48
 overview, 41–42
 structural studies, 44–46, 48
 PMCA pump suppression, 78–80
Store-operated calcium entry (SOCE)
 astroglia, 547, 550
 cancer, 479, 482, 485, 487
 cardiomyocyte, 416, 420
 Huntington's disease, 503
 neurodegenerative disease, 512
 oocyte/egg calcium signaling, 345
 overview, 9–11, 37–39
 prospects for study, 49
 stimulus intensities and activation, 59–60
Syk, 74–75
Synapse-to-nucleus calcium-dependent communication
 activity-dependent metabolic plasticity
 astrocytes, 391–393
 neuronal energy metabolism
 activity-dependent transcription of metabolic
 genes, 393–395
 long-lasting changes in glucose metabolism,
 393, 395–396
 physiological benefits of activity-
 dependent aerobic glycolysis, 396–398
 functional consequences
 activity-dependent control of transcriptional
 permissiveness, 390
 chronic pain, 389–390
 drug addiction, 390
 long-term memory, 386–387
 morphological plasticity, 387–388
 neuroprotection acquisition, 388–389
 mechanisms
 activity-dependent gene transcription, 386
 calcium entry pathways and signal
 propagation, 383–384
 nuclear calcium signaling, 384–386
 overview, 382
 transcriptional response to calcium
 signals, 382–383
Synaptotagmin
 diseases, 285–286
 exocrine cell, 443
 functional overview, 284–285
SYT1, 286
SYT2, 286

- T**
- Tachycardia. See Catecholaminergic polymorphic ventricular tachycardia
- Tacrolimus. See Calcineurin
- TAT-Pep2, 467–469
- T-cell receptor (TCR), endoplasmic reticulum calcium store release, 62–63
- TCR. See T-cell receptor
- TFEB, 208–209
- Tissue calcification. See Calcification
- TLR4, 328
- TMEM16A, 441
- TOP2B, 382–383
- TPC1, 109–111, 204–205, 360–363
- TPC2, 109–111, 114, 204–205, 360–363, 365–368, 370, 372
- TPC3, 111, 204–205, 360–361
- Transient receptor potential (TRP) channels.
See also specific channels
- calcium-binding sites, 30–31
 - calcium/calmodulin interactions, 31
 - calcium pores
 - TRPM4, 30
 - TRPV1, 29
 - TRPV6, 28–29
 - calcium regulation, 19–21
 - gating and cytosolic calcium signaling, 18–19
 - overview, 11, 17–18, 56–57
 - PIP₂ interactions, 32
 - prospects for study, 32
 - structure
 - history of study, 22
 - PKD interactions, 26–27
 - published structures, 23–26
 - subfamily-specific features, 27–28
 - TRPV1, 22, 26
 - TRPC channel regulation at membrane junctions, 60–61
- Transverse and axial tubule system (TATS), 410, 412–413
- TRESK, 330
- Troponin C, 11
- TRP channels. *See* Transient receptor potential channels
- TRPA1, 488
- TRPC1, 444, 490, 550
- TRPC3, 444, 490
- TRPC5, 490
- TRPC6, 483–484
- TRPM2, 117
- TRPM7, 346–347, 530
- TRPM8, 481
- TRPML1
 - exocrine cell membrane contact sites, 438
 - lysosome
 - functions, 208–209
 - ion selectivity, 206–207
 - overview, 205–206
 - regulation, 207–208
 - NAADP receptor patch-clamping studies, 113
- TRPML2, 113
- TRPML3, 202, 438
- TRPV3, 346
- TRPV4, 481, 486–489
- TRPV6, 481, 526
- Tumor microenvironment, calcium signaling, 487–488
- Two-pore channels. *See also specific channels*
- cardiomyocyte, 415
 - embryonic development and cell differentiation role
 - endothelial cell differentiation, 372
 - epithelial cell differentiation, 372–373
 - neuronal differentiation and TPC2 signaling, 368–371
 - osteoclastogenesis and TPC2 signaling, 370, 372
 - overview, 361
 - prospects for study, 373
 - skeletal muscle development, 362–368
- endolysosomal channels, 109–110, 204–205
- human channel properties, 112
- overview, 109, 359–361
- sea urchin egg channel properties, 111
- U**
- Unfolded protein response (UPR), 247
- UPR. *See* Unfolded protein response
- V**
- Vascular smooth muscle cell. *See* Calcification
- Vasoactive intestinal peptide (VIP), 440
- VDAC
 - Bcl-2 protein modulation, 142–145
 - cardiomyocyte, 417
 - isoforms, 185–186
 - structure and function, 142–143
- VEGFD, 388
- VEGFR1, 372
- VEGFR2, 372
- Venetoclax. *See* ABT-199/Venetoclax
- VILIP proteins, 290, 293, 296
- VIP. *See* Vasoactive intestinal peptide
- VMP1, 164
- W**
- WF1, 296
- WNK, 442

This is a free sample of content from Calcium Signaling, Second Edition.
[Click here](#) for more information on how to buy the book.